Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.94 USD | -0.63% | -4.34% | +7.50% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.50% | 1.35B | |
+18.33% | 125B | |
+13.00% | 108B | |
-7.27% | 24.21B | |
+1.83% | 22.78B | |
-10.97% | 17.96B | |
-41.74% | 16.43B | |
-12.96% | 16.37B | |
+0.94% | 13.58B | |
+26.59% | 11.66B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024